Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Blood - 24 Feb 2011

Kawedia Jitesh D, Kaste Sue C, Pei Deqing, Panetta John C, Cai Xiangjun, Cheng Cheng, Neale Geoffrey, Howard Scott C, Evans William E, Pui Ching-Hon, Relling Mary V

Abstract excerpt

Osteonecrosis is a severe glucocorticoid-induced complication of acute lymphoblastic leukemia treatment. We prospectively screened children (n = 364) with magnetic resonance imaging of hips and knees, regardless of symptoms; the cumulative incidence of any (grade 1-4) versus symptomatic (grade 2-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Dexamethasone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Magnetic Resonance Imaging

Share to Osteonecrosis

Share to Pharmacogenetics

Share to Pharmacokinetics

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Prednisone

Source

Open in PubMed Open full text

Identifiers

PMID: 21148812
DOI: 10.1182/blood-2010-10-311969
PMCID: PMC3062406

Genes

ACP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21148812-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.PMID 21148812Read ↗

Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With LeukemiaSemantic proximity Read ↗

Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

A GRIN3A polymorphism may be associated with glucocorticoid-induced symptomatic osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

ALL and osteonecrosis.Semantic proximity Read ↗

Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Genetics of pleiotropic effects of dexamethasone.Semantic proximity Read ↗

A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.Semantic proximity Read ↗

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.